TMO — Thermo Fisher Scientific Inc
Is TMO overbought or oversold? Here is the current MarketMoodz read.
Thermo Fisher Scientific Inc (TMO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $686.79. The rating moved from Overbought to Neutral on November 16, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$686.79
- Last changeMoved from Overbought to Neutral on November 16, 2026
- SectorHealthcare
- IndustryDiagnostics & Research
AI analysis
Thermo Fisher Scientific Inc (TMO) combines a resilient mix of recurring consumables, instruments and high‑margin services that benefit from secular growth in biologics, specialty therapies and diagnostics. Market flows into large‑cap defensive healthcare and distributor shifts toward specialty care reinforce near‑term demand stability. Primary upside catalysts include continued adoption of biopharma outsourcing, recurring consumables growth and accretive M&A. Key vulnerabilities are regulatory/reimbursement changes affecting customer economics, potential softness in capital spending, and integration/margin risks. With muted social sentiment data and a consolidation market tone, the near‑term outlook is steady with upside driven by execution on services growth and sustained consumables demand.
Key factors
- Diversified exposure across life sciences, diagnostics, specialty biopharma services and consumables supports recurring revenue and cash generation
- Strong market position and pricing power in instruments and consumables, which cushions near‑term cyclical swings
- Sector flows favoring large‑cap pharma/healthcare defensives should support relative demand for established healthcare/life‑science names
- Secular growth in biologics, specialty injectable therapies and surgical/OR automation expands addressable market for instruments, reagents and services
- Strategic M&A capability and scale enable cross‑sell into biopharma services, distribution and lab workflows
- Historically solid balance sheet and cash flow profile provide flexibility for capital allocation and tuck‑ins
Risks
- Regulatory and reimbursement pressures (including CMS program integrity changes) that could indirectly affect end‑market demand or customer economics
- Macro slowdown or reduced R&D/capital spending by pharma and academic labs that would weigh instrument sales and services
- Margin pressure from input costs, supply chain disruptions, or pricing competition in select product categories
- Execution risk on integration of acquisitions and delivery of projected synergies
- Competitive dynamics as surgical robotics and new platform entrants expand addressable procedures, potentially compressing pricing in some OEM channels
- Concentration of revenue tied to pharma/bio manufacturing cycles and episodic capital purchases
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for TMO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.